COGT

26.8253.30%
JS

Jessica Sachs

Chief Medical Officer

Dr. Jessica Sachs, M.D., has been Chief Medical Officer of Cogent Biosciences, Inc. (formerly known as Unum Therapeutics Inc.) since July 15, 2019. She was Vice President of Clinical Sciences at Cogent Biosciences, Inc. from April 2017 to July 15, 2019, where she was responsible for the clinical development strategy and medical and translational oversight of the Cogent portfolio. She has experience in oncology and pediatrics. From 2012 to April 2017, Dr. Sachs served as Senior Medical Director of Clinical Research at Takeda Pharmaceutical Company Limited where she led multiple clinical programs in oncology and transplantation. From 2010 to 2012, Dr. Sachs was Associate Director at Genzyme Corporation. Dr. Sachs spent several years at Takeda/Millennium where she led multiple clinical programs in oncology and transplantation, and at Genzyme Corporation, where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital. She completed her fellowship in pediatric hematology and oncology at the Dana Farber Cancer Institute and Children’s Hospital Boston. She received her M.D. from Washington University in St. Louis and her B.S. from Duke University.

Positions